Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00679770 · ClinicalTrials.gov registry record · Phase 2

Study of Different Doses of a Novel Treatment for Onychomycosis

A Phase 2 study of Distal, Subungual Onychomycosis, sponsored by Pfizer.

Completed
Registry status
Phase 2
Development phase
28
Enrollment target
4
Study locations

NCT00679770 is a Phase 2 study of Distal, Subungual Onychomycosis that has completed, run by Pfizer. The registered enrollment target is 28 participants. The trial reports 4 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00679770, a Phase 2 study of Distal, Subungual Onychomycosis, has completed, sponsored by Pfizer.

COMPLETED
Registry status
Phase 2
Development phase
28 participants
Enrollment target
4
Study locations

Study Summary

The purpose of the study is to determine the safety and efficacy of 2.5%, 5.0%, and 7.5% AN2690 Solutions compared to the vehicle alone in the treatment of distal, subungual onychomycosis of the great target toenail.

Interventions

  • DRUG Vehicle
  • DRUG AN2690, 2.5%
  • DRUG AN2690, 5%
  • DRUG AN2690, 7.5%

Study Locations (4)

Texas

  • DermResearch, Inc. - Austin
  • J&S Studies - Bryan
  • Endeavor Clinical Trials, PA & San Antonio Podiatry Associates, PC - San Antonio

New Mexico

  • Academic Dermatology Associates - Albuquerque

Trial Details

FieldValue
Enrollment Target 28 participants
Start Date 2006-06-30
Est. Completion 2007-08-31
Phase Phase 2

Sponsor

Pfizer

1,845 total trials

What the Registry Record Tells You About NCT00679770

The ClinicalTrials.gov registry entry for NCT00679770 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Distal, Subungual Onychomycosis appearing as the primary indexed condition, and to 4 interventions - of which Vehicle is the first listed.

NCT00679770 reports 4 study locations spanning 2 distinct geographic areas - top geographies include Texas, New Mexico.

Frequently Asked Questions

What is clinical trial NCT00679770 about?

NCT00679770 is a clinical study titled "Study of Different Doses of a Novel Treatment for Onychomycosis". The purpose of the study is to determine the safety and efficacy of 2.5%, 5.0%, and 7.5% AN2690 Solutions compared to the vehicle alone in the treatment of distal, subungual onychomycosis of the great target toenail.

What is the current status of trial NCT00679770?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 28 participants. The study started on 2006-06-30. Estimated completion is 2007-08-31.

What conditions does trial NCT00679770 study?

This clinical trial studies the following conditions: Distal, Subungual Onychomycosis.

What interventions are being tested in trial NCT00679770?

The interventions under investigation include: Vehicle (DRUG), AN2690, 2.5% (DRUG), AN2690, 5% (DRUG), AN2690, 7.5% (DRUG).

Who is sponsoring clinical trial NCT00679770?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00679770 being conducted?

This trial has 4 study locations across New Mexico, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Distal, Subungual Onychomycosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.